Selected article for: "detectable virus and respiratory tract"
Author: Zhou, Qiong; Wei, Xiao-Shan; Xiang, Xuan; Wang, Xu; Wang, Zi-Hao; Chen, Virginia; Shannon, Casey P; Tebbutt, Scott J; Kollmann, Tobias R; Fish, Eleanor N
Title: Interferon-a2b treatment for COVID-19
  • Cord-id: ttdzvw1s
  • Document date: 2020_4_10
    • ID: ttdzvw1s
    Snippet: Summary Background The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing. We describe here the clinical course of COVID-19 in a cohort of confirmed cases in Wuhan, China, treated with the repurposed potential experimental therapeutics IFN-α2b, arbidol or a combination of IFN-α2b plus arbidol. Methods 77 adults with confirmed COVID-19 were treated with either nebulized IFN-α2b (5mU,b.i.d.), arbidol (200mg dispersible tablet, t.i.d.) or a combination of IFN-α2b p
    Document: Summary Background The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing. We describe here the clinical course of COVID-19 in a cohort of confirmed cases in Wuhan, China, treated with the repurposed potential experimental therapeutics IFN-α2b, arbidol or a combination of IFN-α2b plus arbidol. Methods 77 adults with confirmed COVID-19 were treated with either nebulized IFN-α2b (5mU,b.i.d.), arbidol (200mg dispersible tablet, t.i.d.) or a combination of IFN-α2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts and blood biochemistry, serum cytokine levels, temperature and blood oxygen saturation levels were recorded for each patient during their hospital stay. Findings Treatment with IFN-α2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. Interpretation IFN-α2b should be investigated as therapy in COVID-19 cases.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and low remain: 1
    • acute ards respiratory distress syndrome and low upper respiratory tract: 1
    • acute inflammation and lopinavir ritonavir: 1, 2, 3, 4, 5
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low remain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome and low upper respiratory tract: 1, 2, 3, 4, 5